Expression and function of the collagen receptor GPVI during megakaryocyte maturation. by Lagrue-Lak-Hal, A. H. et al.
Expression and Function of the Collagen Receptor GPVI during
Megakaryocyte Maturation*
Received for publication, October 5, 2000, and in revised form, December 22, 2000
Published, JBC Papers in Press, January 16, 2001, DOI 10.1074/jbc.M009117200
Anne-He´le`ne Lagrue-Lak-Hal‡, Najet Debili§, Gillian Kingbury¶, Christelle Lecut‡,
Jean-Pierre Le Couedic§, Jean-Luc Villeval¶, Martine Jandrot-Perrus‡, and
William Vainchenker§i
From ‡INSERM E9907, Faculte´ Xavier Bichat, 75870 Paris Cedex 18, Paris, France, §INSERM U362, Institut Gustave
Roussy, Villejuif 94805, France, and ¶Millenium Pharmaceuticals Inc., Cambridge, Massachusetts 02139
In this report, the expression and function of the plate-
let collagen receptor glycoprotein VI (GPVI) were studied
in human megakaryocytes during differentiation and
maturation of mobilized blood and cord blood derived
CD341 cells. By flow cytometry, using an anti-GPVI mono-
clonal antibody or convulxin, a GPVI-specific ligand,
GPVI was detected only on CD411 cells including some
CD411/CD341 cells, suggesting expression at a stage of
differentiation similar to CD41. These results were con-
firmed at the mRNA level using reverse transcription-
polymerase chain reaction. GPVI expression was low dur-
ing megakaryocytic differentiation but increased in the
more mature megakaryocytes (CD41high). As in platelets,
megakaryocyte GPVI associates with the Fc receptor g
chain (FcRg). The FcR g chain was detected at the RNA
and protein level at all stages of megakaryocyte matura-
tion preceding the expression of GPVI. The other collagen
receptor, a2b1 integrin (CD49b/CD29), had a pattern of
expression similar to GPVI. Megakaryocytic GPVI was
recognized as a 55-kDa protein by immunoblotting and
ligand blotting, and thus it presented a slightly lower
apparent molecular mass than platelet GPVI (58 kDa).
Megakaryocytes began to adhere to immobilized con-
vulxin via GPVI after only 8–10 days of culture, at a time
when megakaryocytes were maturing. At this stage of
maturation, they also adhered to immobilized collagen by
a2b1 integrin-dependent and -independent mechanisms.
Convulxin induced a very similar pattern of protein tyro-
sine phosphorylation in megakaryocytes and platelets in-
cluding Syk, FcRg, and PLCg2. Our results showed that
GPVI is expressed early during megakaryocytic differen-
tiation but functionally allows megakaryocyte adherence
to collagen only at late stages of differentiation when its
expression increases.
At sites of vascular injury, platelets adhere and are activated
by contact with collagen fibers exposed with the subendothe-
lium matrix leading to thrombus formation. Several collagen
receptors are present on platelets: integrin a2b1 (CD49b/
CD29), GPIV1 (CD36), GPVI, p65, and a recently cloned type
III collagen receptor (1, 2). The direct interaction between
collagen and integrin a2b1 adheres platelets at the collagen
surface, but platelet activation and thrombus formation and
attachment are subsequently mainly supported by GPVI. In
addition to collagen, two GPVI-specific ligands have been de-
scribed: collagen-related peptides (3) and convulxin, a snake
venom protein (4). GPVI has recently been characterized as a
new member of the immunoglobulin superfamily of cell-associ-
ated receptors, in which expression is restricted to the hema-
topoietic lineage (5–7). It is coexpressed as a noncovalent com-
plex with the common immunoglobulin receptor g (FcRg) chain,
which acts as the signaling subunit of the complex (8, 9) As a
consequence, signaling pathways coupled to GPVI dimerization
are identical to those coupled to other immune receptors; tyro-
sine phosphorylation of the FcR g chain on its immunoreceptor
tyrosine-based motif (ITAM) by a Src familly kinase (8, 10, 11)
allows recruitment by the SH2 (Src homology 2) domain of
P72Syk that is in turn phosphorylated and activated. Down-
stream of Syk, PLCg2 is activated, leading to platelet aggrega-
tion and dense granule secretion (12).
Expression of platelet receptors during megakaryocyte dif-
ferentiation discriminates different stages of megakaryocyte
maturation (13, 14). GPIIb/GPIIIa (CD41/CD61) are platelet
proteins that are the first expressed during megakaryocyte
differentiation, although their expression is not entirely spe-
cific of this cell lineage (15, 16). A fraction of megakaryocyte
progenitors, colony-forming unit megauaryocytes, express
GPIIb and GPIIIa (17). Later in differentiation, promegakaryo-
blasts and megakaryoblasts also express the GPIbzGPIX com-
plex (CD42) and CD36. More recently, it has been shown that
GPV, in which the promoter has been cloned, is expressed
during megakaryocyte differentiation even later than the
GPIbzGPIX complex (18).
Our study was designed to characterize GPVI expression
during megakaryocytopoiesis and to determine more precisely
the kinetics of GPVI expression and its functionality in
megakaryocytes. Cell surface expression of GPVI was studied
by flow cytometry in comparison with cell surface expression of
CD49b and by blotting experiments using specific antibodies or
one specific ligand, convulxin. Expression of GPVI and FcR g
chain mRNA was studied by RT-PCR. Functional characteriza-
tion was performed by measuring adhesion to immobilized
collagen or convulxin and by studying the signals coupled to
GPVI. Our results indicate that GPVI is expressed at an early
stage of megakaryocyte differentiation but at low levels and
that it is functional in mature megakaryocytes, suggesting that
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GPVI may regulate thrombopoiesis and platelet release in vivo
through its interactions with collagen.
EXPERIMENTAL PROCEDURES
Materials—Convulxin was purified from the venom of Crotalus dur-
issus terrificus (from Fundac¸a˜o Ezequiel Dias (FUNED), Minas Gerais,
Brazil or Latoxan, Valence, France) as previously described (19). Con-
vulxin was labeled with 125I using the Iodogen procedure (Pierce) and
Na125I (Amersham Pharmacia Biotech) or was coupled to fluorescein
(FITC) as previously described (7).
The anti-GPVI monoclonal antibody (mAb), 3J24z2, was produced by
immunizing Balb/c mice with the DNA encoding a fusion protein cor-
responding to the extracellular domain of GPVI (residues 1–269) fused
at its C terminus via a 3 Ala linker to the human IgG1 Fc sequence
(shGPVI-Fc)7 using the Rapid Immunization Gene Gun delivery as
described (20). Mice were boosted with 100 mg of intravenous shG-
PVI-Fc 4 days prior to fusion. Spleen cells of one mouse were fused with
SP2/0 myeloma cells using PEG 1500, and hybridoma lines were
screened for secretion of GPVI-specific antibodies by enzyme-linked
immunoassay on plate-bound shGPVI-Fc. Antibodies were isotyped,
and 3J24z2 was shown to be IgG1. Selected cell lines were cloned using
ClonalCellTM-HY medium D (Stem Cell Technology, Vancouver, British
Columbia, Canada). Ascitic fluids were produced, and antibodies were
purified by chromatography on protein A-Sepharose (Amersham Phar-
macia Biotech). Purified 3J24z2 does not inhibit collagen- or convulxin-
induced platelet activation but behaves as a mild platelet agonist in-
ducing a low level of aggregation (;10%) after prolonged incubation (15
min) at 37 °C with stirring. 3J24z2 recognizes nonreduced GPVI in
immunoblotting experiments. 3J24z2 was conjugated to FITC by the
same method as used for convulxin (7). Polyclonal anti-GPVI IgGs were
purified from a patient plasma (21), kindly provided by Dr. M. Okuma,
and Fab fragments were from the same batch as in previous studies (4).
The anti-integrin a2b1 monoclonal antibody was kindly provided by Dr.
B Coller (Mount Sinai Medical Center, New York, NY) (22).
Collagen type I (from equine tendon) or collagen from fetal calf skin
was purchased from Chrono-Log Corp. (Haverton, PA) or Horm (Hor-
mon-Chemie, Munich, Germany) and Bio/Data Corporation (Horsham,
PA), respectively. The following mAbs were purchased from Beckman-
Coulter (Marseille, France): FITC anti-CD49b mAb (anti-integrin a2;
clone Gi9), R-PE anti-CD41 mAb, R-PE-Cy5 anti-CD34 mAb and FITC
anti-CD42b mAbs. The anti-PY 4G10 was obtained from Upstate Bio-
technology (Euromedex, Souffelweyersheim, France) as the mAb di-
rected against the FcR g chain that was conjugated to FITC. Anti-
phosphotyrosine (PY20), anti-Syk (LR Syk), and anti-PLCg2 (Q20)
mAbs were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
The peroxidase-coupled sheep anti-mouse IgG and the chemilumines-
cent reagent ECL were from Amersham Pharmacia Biotech. Phenylars-
ine oxide, vanadate, leupeptin, PMSF, aprotinin, and Nonidet P-40
were obtained from Sigma, and polyvinylidene difluoride (PVDF) mem-
branes from Millipore (Bedford, MA).
Purification of CD341 Cells—After obtaining informed consent, an
aliquot of leukapheresis from adult patients, after mobilization by
chemotherapy and granulocyte/colony-stimulating factor, was obtained
for research purposes. Human umbilical blood cells were obtained from
full term deliveries under guidelines established by the Ethical Com-
mittee. Cells were separated over a Ficoll-metrizoate gradient (Lym-
phoprep, Nycomed Pharma, Oslo, Norway). CD341 cells were then
isolated by a positive selection using the Miltenyi immunomagnetic
bead technique according to the manufacturer’s protocol. The purity
was about 90% after two passages through the column as estimated by
flow cytometry.
In Vitro Liquid Cultures of Megakaryocytes from CD341 Cells—
CD341 cells were grown for 5–14 days in “serum-free” Iscove’s modified
Dulbecco’s medium (Life Technologies, Inc.) prepared as previously
reported (23). The medium was supplemented with a combination of
pegylated recombinant human megakaryocyte growth and development
factor (PEG-rHuMGDF 10 ng/ml, a generous gift from Kirin, Tokyo,
Japan), a truncated form of thrombopoietin (TPO), and 50 ng/ml recom-
binant human stem cell factor (a generous gift from Amgen, Thousand
Oaks, CA) for flow cytometry or with PEG-rHuMGDF alone for bio-
chemical and adhesion experiments.
Cell Sorting of Different CD41 Subsets—Megakaryocytes at different
stages of differentiation were obtained after 6 days of culture. Cells
were incubated with a mixture of a FITC anti-CD42a, R-PE anti-C-
D41a, and R-PE-Cy5 anti-CD34 mAbs for 30 min at 4 °C in their culture
medium. Cells were washed in culture medium and sorted into the
following five populations using a FACS Vantage flow cytometer (Bec-
ton Dickinson) equipped with an argon laser (Coherent Radiation, Palo
Alto, CA) and a 100-mm nozzle: CD341CD41a2, CD341CD41a1C-
D42a2, CD342CD41a1CD42a2, CD342CD41a1CD42a1, and the entire
CD41high cells corresponding to mature megakaryocytes. Each cell fra-
ction except the CD41high one was re-sorted to ensure a purity level
greater than 97%.
RT-PCR—RNA was extracted according to the technique of Chomc-
zynsky and Sacchi (24). Total RNA (500 ng-1 mg) was denatured at
70 °C for 10 min and then reverse-transcribed with avian myeloblasto-
sis leukemia virus reverse transcriptase (20 units, Promega, Madison,
WI) at 42 °C for 1 h with random hexanucleotides (200 ng, Amersham
Pharmacia Biotech) as primers in a final volume of 50 ml.
After reverse transcription, each sample was subjected to amplifica-
tion of GPVI, FcR g chain, or b2 microglobulin cDNA. The sequences of
the specific primers for GPVI, FcR g chain, and b2 microglobulin were:
59-TTCTGTCTTGGGCTGTGTCTG-39, 59-AGATGATTCCAGCAGTGG-
TCTT-39, and 59-CCTGAAGCTGACAGCATTCGG-39 for sense primers,
respectively, and 59-CCCGCCAGGATTATTAGGATC-39, 59-TCTTTAA-
CAGGGAGGAGGAACC-39, and 59-CTCCTAGAGCTACCTGTGGAG-39
for antisense primers, respectively.
PCR was performed as previously reported in a 25-ml reaction mix-
ture (containing 30 pmol of primers for GPVI and FcR g chain ampli-
fications and 10 pmol of primers for b2 microglobulin amplification) in
ATGC buffer. The reaction mixture was subjected to denaturation for 5
min at 95 °C and then amplified by 35 cycles as previouly reported (7).
PCR products (9 ml) were electrophoresed on a 2% agarose gel. Frag-
ments were visualized by illumination after ethidium bromide staining.
MassRuler DNA Ladder, low range (MBI, Fermentas Vilnius, Lithua-
nia) was used as a size marker.
Flow Cytometry—Cells were studied from day 5 to day 14 of culture.
To study GPVI during megakaryocyte maturation, cells were simulta-
neously labeled for 30 min with R-PE-Cy5 anti-CD34 mAb, R-PE anti-
CD41 mAb, and a FITC anti-CD42 or FITC anti-GPVI mAb (3J24-2) or
FITC anti-CD49b mAb and subsequently washed. Isotype IgGs were
used as controls. In some experiments, cells were labeled by the R-PE
anti-CD41 mAb or R-PE anti-CD34 mAb and FITC-convulxin (20 nM).
Nonspecific labeling was measured using FITC-coupled bothrojaracin
(20 nM), another protein from the same C-type lectin snake venom
protein family as convulxin but which does not bind to platelets (7). For
studying the expression of the FcR g chain, cells were incubated with
R-PE CD41, washed, fixed by 0.5% paraformaldehyde for 15 min, and
then permeabilized by 0.1% Triton X-100, washed, and incubated with
the FITC anti-FcR g chain antibody. Cells were then analyzed by flow
cytometry using a FACSort flow cytometer (Becton Dickinson, Franklin
Lakes, NJ).
Adhesion to Immobilized Collagen or Convulxin—Adhesion experi-
ments were performed using cells cultured in the presence of TPO
alone, a culture condition that allows the growth of megakaryocytes
with a high level of purity (about 90%). Adhesion was measured in
static conditions on microtitration plates as previously described (4, 7).
Briefly, collagen (2 mg) and convulxin (1.5 mg) were immobilized on
Immulon II plates. After saturation with BSA, megakaryocytes were
added for 60 min at 37 °C in the presence or the absence of 10 mM
EDTA. Megakaryocyte adherence was quantified by measuring alka-
line phosphatase activity as follows: 100 ml of 0.1 M sodium citrate, pH
5.4, containing 0.3% v/v Triton and 7 mM of paranitrophenylphosphate
were added to emptied wells. Reaction was stopped with 1 M NaOH, and
optical density was measured at 405 nm. Nonspecific adhesion was
measured using wells coated with BSA. The percentage of adherent
cells was calculated from a calibration curve performed using cells in
suspension.
Immunoblotting and Ligand Blotting—Cells (2.106/ml) were lysed in
a radioimmune precipitation buffer composed of 1% v/v Nonidet P-40 in
12 mM Tris, 300 mM NaCl, 12 mM EDTA containing 0.2 mM PMSF, 2 mM
leupeptin, and 5 Kallikrein inhibitory units (KIU) of aprotinin. Proteins
(40 mg) were separated by SDS-polyacrylamide gel electrophoresis and
transferred to PVDF membranes (6, 19). Membranes were incubated
with polyclonal anti-GPVI IgG or with 3J24-2 or the anti-FcR g chain
mAbs. IgGs were detected with peroxidase-coupled protein A for the
polyclonal antibody or peroxidase-coupled goat anti-mouse IgG for the
mAbs and revealed by chemiluminescence. Ligand blotting was per-
formed as previously reported (4, 7) using 125I-labeled convulxin and
autoradiography.
Tyrosyl phosphorylations were studied on cells cultured in the pres-
ence of TPO alone. Megakaryocytes (1.106 cells/ml) in Hanks buffer
containing 2 mg/ml BSA were incubated in an aggregometer at 37 °C
under stirring conditions (1100 rpm). Convulxin (10 nM) or collagen
(100 mg/ml) was added to the suspension for 6 min. Incubation was
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stopped by the addition of 100 ml from a mixture containing 65 mM
EDTA, 33 mM vanadate, and 2 mM phenylarsin oxide (PAO) (25). Sam-
ples were centrifuged for 1 min at 13,000 3 g. Pellets were then lysed
in a buffer containing 1% v/v Triton, 0.1% w/v SDS, 5% b-mercaptoeth-
anol, 4.2 mM EDTA, 24 mM vanadate, 4 mM PAO, 0.25 mg/ml pefabloc,
1.5 mM PMSF, 500 KIU/ml aprotinin, and 5 mg/ml leupeptin (Sigma).
Proteins were separated by SDS- polyacrylamide gel electrophoresis
and transferred to PVDF membranes. Membranes were incubated with
the anti-phosphotyrosine mAb PY20 followed by peroxidase-coupled
anti-mouse IgGs and chemiluminescence.
Immunoprecipitation—Megakaryocytes (0.5 3 106) or platelets
(2.5 3 108) were lysed by the addition of a radioimmune precipitation
buffer containing 1% (v/v) Nonidet P-40, 5 mM vanadate, 2 mM PMSF,
0.25 mg/ml pefabloc, 500 KIU/ml aprotinin, and 5 mg/ml leupeptin.
Samples were precleared by incubation with protein A-Sepharose for 15
min at 4 °C and centrifuged to reduce nonspecific signal (25). Lysates
were incubated with anti-PLCg2 mAb, anti-Syk mAb, or 3J24-2 mAb
overnight at 4 °C and then incubated with the protein A/G-Sepharose
for 2 h at 4 °C. Immunoprecipitated proteins were solubilized by 2%
(w/v) SDS, reduced with 5% (v/v) 2-mercaptoethanol, except for GPVI
immunoprecipitation, and finally transferred to PVDF.
RESULTS
Study of GPVI Expression during Megakaryocyte Differenti-
ation—To determine expression of GPVI during megakaryo-
cyte differentiation, we used a new mAb called 3J24z2 directed
against human GPVI and the binding of a specific ligand,
convulxin. Megakaryocyte cultures were performed from
CD341 cells isolated from cord blood or leukapheresis and were
FIG. 1. Expression of GPVI and a2b1 integrin using flow cytometry on mobilized peripheral blood CD34
1. Cells were analyzed on a
FACSort flow cytometer at day 5 or 10 in in vitro culture. Cells (100,000 cells/50 ml) were incubated for 30 min at 4 °C with R-PE-Cy5 anti-CD34
mAb, R-PE anti-CD41 mAb, FITC anti-CD42 mAb, FITC anti-CD49b mAb, or FITC anti-GPVI mAb as described under “Experimental Procedures,”
and controls were performed with R-PE-Cy5 IgG1 mouse antibody, R-PE IgG1 mouse antibody, or FITC IgG1 mouse antibody. Histograms of
fluorescence were determined in CD41 negative cells (CD412), immature megakaryocytic cells (CD411), and more mature megakaryocytic cells
(CD4121). FITC anti-CD42 labeling (green line), FITC anti-CD49b labeling (blue line), and FITC anti-GPVI labeling (red line) were compared with
control FITC IgG1 mouse antibody (black line). The results are representative of five independent experiments.
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studied at different days of culture from days 5 to 14. To
analyze the precise stage at which GPVI is expressed, a triple
staining technique was performed using the CD34 and CD41
antigens as markers of differentiation; CD411 cells corre-
sponded to immature megakaryocytic cells, whereas CD4121
cells to mature megakaryocytes. In addition, expression of
GPVI was compared with that of another collagen receptor,
CD49b (a2b1integrin), and with GPIba.
Using megakaryocytes derived in vitro by culture in TPO,
GPVI was present only on the CD411 cell subset. GPVI was
expressed on CD411 cells regardless of time in culture (5, 10
(Figs. 1 and 2), or 14 days (data not shown)). Expression was
also not dependent on the source of CD341 cells, blood-mobi-
lized cells (Fig. 1), or cord blood (Fig. 2). GPVI was also present
on both CD341 cells (Figs. 1 and 3) but only in the
CD341CD411 cell subset. However, expression of GPVI was
low during megakaryocytic differentiation and was just over
the background in the CD411 cells (see histograms in Figs.
1–3). Expression of GPVI increased with maturation in parallel
with the augmentation of CD41 antigen on the cell surface (see
dot plots in Figs. 1–3). CD49b had a similar pattern of expres-
sion to GPVI in these cultures with a weak expression in the
CD411 cells and increased expression in the CD4121 cells
(Figs. 1–3). However, there was a great variation in the expres-
sion of CD49b. In some experiments, the level of CD49b was at
the threshold of detection (Figs. 1 and 2), whereas in other
experiments it was at an intermediate point between the level
of CD42 and GPVI (Fig. 3). This heterogeneity in the expres-
sion of CD49b might be the consequence of CD49b polymor-
phisms(26). Expression of CD42 was slightly different from
that of GPVI. Indeed, its level was much higher and increased
linearly with the CD41 antigen (Figs. 1–3). However, it ap-
pears, especially in experiments with cord blood cells, that a
fraction of CD411 cells did not express CD42 (see Fig. 2, Day 5).
Together, these results indicate a very weak expression of
GPVI and CD49b on immature megakaryocytes. The two mol-
ecules increase at the end of the maturation concurrent with
CD41 expression, but their expression remains much weaker
than that of CD42. To confirm that GPVI was synthesized early
in differentiation, RT-PCR analysis was performed on different
cell fractions sorted on the expression of CD34, CD41, and
CD42. GPVI mRNA was detected in all CD411 cell fractions
including those that also express CD34, whereas it was not
detected in the CD412 cell fraction (Fig. 4A).
To determine whether functional binding of megakaryocyte
GPVI to a specific ligand takes place, flow cytometry was per-
FIG. 2. Expression of GPVI and a2b1 integrin using flow cytometry on cord blood CD34
1. Experiments were performed as described in
Fig. 1. Cultures were performed from cord blood CD341 cells and analyzed at days 5 and 10. Histograms of fluorescence were determined in CD412,
CD411, and CD4121 cells. FITC anti-CD42 labeling (green line), FITC anti-CD49b labeling (blue line), and FITC anti-GPVI labeling (red line) were
compared with control FITC IgG1 mouse antibody (black line). The results are representative of three independent experiments.
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formed using FITC-convulxin and R-PE anti-CD41 mAb or
R-PE anti-CD34 mAb. The results confirmed those obtained
with the anti-GPVI mAb; FITC-convulxin labeled CD411 cells
just over the threshold when compared with the control snake
venom protein, FITC-coupled bothrojaracin (Fig. 5, Day 8).
This level of binding was low but much more pronounced in
mature megakaryocytes (CD4121) (Fig. 5). Altogether, these
results indicate that GPVI is expressed at low levels during
megakaryocyte differentiation and might be functional.
Megakaryocyte Express GPVI as a 55-kDa Protein Associated
with the FcR g Chain—Expression of GPVI by megakaryocytes
was further characterized by immunoblotting and ligand blot-
ting and by immunoprecipitation. As previously reported,
platelet GPVI was detected as a 58-kDa band protein with both
the anti-GPVI mAb (Fig. 6, lane a) and 125I-convulxin (Fig. 6,
lane d). The anti-GPVI mAb (Fig. 6, lane b) as well as 125I-
convulxin (Fig. 6, lane e) both labeled a 55-kDa band in
megakaryocyte lysates, suggesting that GPVI expressed by
megakaryocytes has a slightly lower molecular mass than
platelet GPVI. One characteristic behavior of platelet GPVI as
of recombinant GPVI in immunoblotting experiments is that
convulxin blocks the binding of polyclonal anti-GPVI antibod-
ies. (4, 7) The same observation is made for megakaryocyte
GPVI (Fig. 6, lanes g–h). At least, 3J24.2 precipitated a 56-kDa
protein from megakaryocyte lysates, which was recognized by
125I-convulxin (Fig. 6, lanes c and d). Together, these results
indicate that megakaryocytes produce GPVI.
In platelets, FcR g chain is associated as a noncovalent
complex with GPVI and acts as the signaling chain (8, 11). We
checked whether the FcR g chain is also expressed by adult or
neonate CD341-derived megakaryocytes. Using FITC-coupled
antibody, which binds to the intracellular domain of the g chain
and permeabilized cells in flow cytometry studies, FcR g chain
FIG. 3. Differences in CD49b expression among patients. Similar experiments as in Fig. 1 were performed on the cells from another donor.
A higher level of CD49b expression is observed, probably reflecting integrin a2b1 polymorphisms (29). Of seven individuals, CD49b expression was
only found highly expressed in two.
FIG. 4. Expression of GPVI using RT-PCR. Megakaryocytes at
different stage of differentiation were obtained after 6 days of culture
and were sorted according to their immunophenotype into five different
populations: 1) CD341CD41a1CD422, 2) CD342CD41a1CD42a2, 3)
CD342CD41a21CD42a21, 4) CD341CD41a2, and 5) the entire CD4121
cell population, corresponding to mature megakaryocytes. GPVI and b2
microglobulin (b2) transcripts were amplified in panel A. The high
molecular weight fragment (830 bp) is generated from GPVI primers,
and the low molecular weight fragment (603 bp) is generated from the
b2 microglobulin primers. FcR g chain and b2 microglobulin transcripts
were amplified in panel B. The high molecular weight fragment (603 bp)
is generated from the b2 microglobulin primers, and the low molecular
weight fragment (429 bp) is generated from the FcR g chain primers.
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was detected in all cells, i.e. in CD412 cells as well as in CD411
cells (Fig. 7). Accordingly, FcR g chain mRNA was detected by
RT-PCR in megakaryocytes, whatever their stage of matura-
tion, as well as in CD341CD412 cells. By immunoblotting with
the anti-FcR g chain mAb, an intense doublet corresponding to
FcRg was detected in megakaryocyte lysates (Fig. 7). Further-
more, as already observed with platelet lysates (9) or for re-
combinant GPVI (7), FcRg was coprecipitated with GPVI, in-
dicating that both proteins are noncovalently associated in
megakaryocytes (Fig. 7)
These results indicate that megakaryocytes express GPVI as
a complex with its signaling subunit FcR g chain. Thus, in
subsequent experiments we investigated whether the signaling
pathway coupled to GPVI was functional in megakaryocytes.
Megakaryocyte Adhesion to Immobilized Collagen or Con-
vulxin Involves GPVI and Integrin a2b1—GPVI is responsible
for platelet adhesion to immobilized convulxin and contributes
to the Mg21-independent platelet adhesion to collagen in a
static model of adherence (27, 28), whereas a2b1 integrin serves
as a Mg21-dependent platelet receptor for type I collagen both
in static conditions and in flow (22, 29).
At day 6 of culture, the number of megakaryocytes that
adhered to immobilized collagen or convulxin was very low,
only slightly above the level of nonspecific binding to immobi-
lized BSA (Fig. 8A). Later in the maturation, adhesion of
megakaryocytes to immobilized collagen or convulxin increased
(12- and 22-fold, respectively, at day 9; 18- and 30-fold at day
14; Fig. 8, B and C). Adhesion to immobilized convulxin was
inhibited in part by the polyclonal anti-GPVI Fab fragments
(data not shown) as already observed for platelet adhesion to
immobilized convulxin (4). Megakaryocyte adhesion to immo-
bilized collagen was reduced in the presence of the anti-inte-
FIG. 5. Expression of GPVI by mobi-
lized CD341 using FITC-convulxin.
Cells (100,000 cells/50 ml) were incubated
for 30 min at 4 °C with either R-PE anti-
CD34 mAb or R-PE anti-CD41 mAb and
FITC-convulxin. Controls were performed
with R-PE-IgG1 mouse antibody or with
FITC-bothrojaracin. Cells were analyzed
at day 5 or day 8 of mobilized blood
CD341 cell cultures.
FIG. 6. Expression of GPVI using
immunoblotting, immunoprecipita-
tion, and ligand blotting. Megakaryo-
cyte (lanes b and f–h) and platelet (lanes a
and e) proteins were solubilized in SDS,
separated on 10% acrylamide slab gels,
and transferred to PVDF membranes. Al-
ternatively, megakaryocyte proteins were
immunoprecipitated by the anti-GPVI
mAb 3J24.2 before electrophoresis (lanes
c and d). Proteins were detected by immu-
noblotting with 3J24.2 (lanes a–c), ligand
blotting with 125I-convulxin (lanes d–f), or
immunoblotting with the polyclonal anti-
GPVI antibody in the absence (lane g) or
presence of cold convulxin (lane h). Detec-
tion was performed using peroxidase-cou-
pled anti-mouse IgGs for 3J24.2, peroxi-
dase-coupled protein A for the polyclonal
antibody, and chemiluminescence or di-
rect autoradiography for 125I-convulxin.
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grin a2b1 mAb 6F1 (data not shown), suggesting that the inte-
grin is involved in adhesion (22). In fact, EDTA also reduced
megakaryocyte adhesion to collagen, and its inhibitory effect
increased with maturation increasing from 60% at day 9 to 80%
at day 14 of culture. Together, these results suggest that the
combined expression of GPVI and a2b1 integrin is too low at the
earlier stage of maturation to allow the multiple interactions
required for adhesion to the immobilized collagen. Later in the
maturation, adhesion of megakaryocytes to convulxin indicates
that GPVI is functional and adhesion to collagen may be via
either GPVI or a2b1. However, as shown by the greater inhib-
itory effect of EDTA at day 14 compared with day 9, a2b1
integrin is the major contributor to megakaryocyte adhesion to
collagen later in differentiation.
Collagen and Convulxin Trigger Protein Tyrosine Phosphoryla-
tions in Megakaryocytes—GPVI dimerization by its ligands is cou-
pled to a very potent signaling pathway, which involves activation
of a cascade of tyrosine kinases and which culminates in the phos-
phorylation and activation of PLCg2 leading to platelet activation
(8, 30, 31). To further characterize the functional state of GPVI in
megakaryocytes, we analyzed protein tyrosine phosphorylation in
response to convulxin or collagen. Adult CD341-derived mega-
karyocytes of the same culture were studied sequentially. This
approach allowed us to study the pattern of tyrosine phosphoryla-
tion according to maturation because cultures are partially syn-
chronized (see Figs. 1 and 2). The addition of convulxin or collagen
to the cell suspension at 37 °C with stirring resulted in a slight
transient increase in light transmission comparable with the light
transmission change observed during platelet shape change (not
shown). The pattern of tyrosyl-phosphorylated proteins from day 9
cultured megakaryocytes and from platelets is shown in Fig. 9A.
Before activation, some proteins were phosphorylated in both plate-
lets (lane 4) and megakaryocytes (lane 1), most notably a doublet at
55 kDa, and an additional low molecular mass protein (;30 kDa)
was detected in megakaryocytes. In both cell types, additional
proteins were phosphorylated after incubation with convulxin to
give bands at 145, 120, 105, and 72 kDa. However, a phosphoryl-
ated 38-kDa protein was detected in platelets as in previous studies
(25, 30) but not in megakaryocytes. Megakaryocyte incubation with
collagen also resulted in the tyrosine phosphorylation of these pro-
teins but to a much lower extent than convulxin, as already re-
ported for platelets (25).
The pattern of phosphorylation obtained with megakaryocytes
from the same culture at different stages of maturation is shown in
Fig. 9B. With equal sample loading (5 3 105 cells in each sample)
and exposure, differences in the intensity of phosphorylated bands
were observed according to maturation. Convulxin- or collagen-
induced protein tyrosine phosphorylations were very faint at day 6.
The intensity of the signal greatly increased at day 9 parallel to
GPVI expression but decreased at day 14 (Fig. 9C), suggesting that
the efficiency of GPVI-coupled signals decreases at this late stage of
maturation. In platelets, p72Syk and PLCg2 are tyrosine-phospho-
rylated upon GPVI activation by convulxin (25, 30, 32). Among the
different proteins phosphorylated upon incubation of megakaryo-
cytes with collagen or convulxin, bands with the same migration as
p72Syk and PLCg2 were also observed at 72 and 145 kDa, respec-
tively. p72Syk and PLCg2 were immunoprecipitated from mega-
karyocytes (day 10 culture) or from platelets, before or after stim-
ulation by convulxin or collagen, and analyzed for their content in
phosphotyrosine (Fig. 10). PLCg2 was tyrosine-phosphorylated only
upon megakaryocyte and platelet activation by collagen or con-
vulxin. p72Syk was very slightly phosphorylated in nonactivated
megakaryocytes and platelets, but the intensity of the band in-
FIG. 7. Expression of the FcR g chain using flow cytometry on
mobilized CD341 and immunoblotting. Cells (100,000 cells/50 ml)
were incubated for 30 min at 4 °C with FITC anti-FcRg polyclonal
antibody after permeabilization with 0.1% Triton X-100. Controls were
performed with FITC IgG1 mouse antibody. Mobilized blood CD34
1
cells were analyzed at day 10 of culture. Three experiments were
performed, which gave identical results. Lower left, megakaryocyte
(MK) and platelet (Pl) proteins were separated on 12% acrylamide gels,
transferred onto PVDF membranes, and probed with the polyclonal
anti-FcR g chain antibody. Proteins were revealed using a peroxidase-
coupled secondary antibody and chemiluminescence. FcR g chain mi-
grates as a doublet. Lower right, GPVI was immunoprecipitated (IP)
from platelet or megakaryocyte lysates using 3J24.2, and precipitated
proteins were immunoblotted (IB) using the anti-FcR g chain antibody.
FIG. 8. Adhesion of cultured
megakaryocytes to immobilized con-
vulxin and immobilized collagen.
Megakaryocytes (200,000 cells/ml) obtained
from blood-mobilized CD341 cells cultured
in the presence of TPO at day 6 (A), day 9
(B), or day 14 (C) were added to microtitra-
tion plates coated with convulxin or collagen
type I. After washing, detection of adherent
megakaryocytes was performed by meas-
uring alkaline phosphatase activity. Non-
specific adhesion was detected on BSA-
coated wells (lane a). Megakaryocytes were
incubated with immobilized convulxin (lane
b) or with immobilized-collagen in the ab-
sence (lane c) or presence of EDTA (lane d)
for 1 h at 37 °C. The results are the mean 6
S.E. of triplicate experiments.
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creased upon incubation with collagen or convulxin. In addition, a
phosphorylated low molecular weight protein corresponding to
FcRg was coprecipitated with Syk upon activation of megakaryo-
cytes and platelets by collagen or by convulxin, indicating that Syk
is recruited by phosphorylated FcR g chain upon GPVI activation.
Together, these results indicate that the signaling pathway coupled
to GPVI is functional in megakaryocytes.
DISCUSSION
Megakaryocyte maturation occurs in the marrow, whereas pro-
platelet formation and platelet release takes place in the blood
stream either in marrow sinusoids or in the general circulation
(33). It is thus likely that specific mechanisms exist for the adhesion
of progenitors to bone marrow stroma cells or to extracellular ma-
trix proteins during maturation. On the other hand, to release
platelets, megakaryocytes have to migrate through the endothelial
barrier and cross the extracellular matrix, where they may interact
with adhesive proteins such as fibronectin and collagen. In plate-
lets, the synergy of the two collagen receptors a2b1 and GPVI is
important in mediating adhesion and in subsequent platelet secre-
tion and aggregation (31). The precise expression of these two
proteins and their function during megakaryocyte differentiation
are poorly understood. Recently, GPVI has been cloned, and this
collagen receptor seems to be specific to the megakaryocyte/platelet
lineage (5, 7). Thus, it is now possible to study the expression and
function of GPVI during megakaryocyte maturation.
Based on the response to collagen-related peptides, GPVI
signaling has been proposed to occur only in mature
megakaryocytes (34–36). Because FcR g chain is expressed in
several megakaryocytic cell lines in which GPVI has not been
detected, it was suggested that GPVI could be a late marker
of megakaryocyte differentiation in contrast to FcR g chain
(37). Here we have directly studied the expression of GPVI
during megakaryocytic differentiation using a culture system
from CD341 cell. By flow cytometry, the pattern of GPVI
expression partially mimicked that of CD41. Indeed, GPVI
expression was found only in cells expressing CD41 including
CD41low cells. However, expression was weak, just at the
threshold of detection, in these immature cells, and expres-
sion of GPVI is seen clearly only in the brightest CD411 cells
corresponding to mature megakaryocytes. The fact that GPVI
was expressed at a low level in immature megakaryocytic
cells, including those expressing CD34, was confirmed by
RT-PCR after cell sorting. Interestingly, expression of GPVI
was quite similar to that of CD49b, which was also considered
as a late marker of megakaryocyte differentiation. There is
increasing evidence that the CD41low cell population is not
committed to the megakaryocytic lineage. Thus, it is possible
that the GPVI expression is not entirely specific to the
megakaryocytic lineage and might be expressed at low level
on nonmegakaryocytic progenitor cells. However, prelimi-
nary results suggest that the majority of the CD341GPVI1
cells are late megakaryocyte progenitors.2
Studies of the promoter regions and of transgenic mice have
shown that platelet-restricted genes are controlled by two types
2 A.-H. Lagrue-Lak-Hal, N. Debili, G. Kingbury,, C. Lecut, J.-P. Le
Couedic, J.-L. Villeval, M. Jandrot-Perrus, and W. Vainchenker, unpub-
lished results.
FIG. 9. Convulxin- and collagen-triggered protein tyrosine
phosphorylation in human megakaryocytes. In A, megakaryocytes
obtained from CD341 cells cultured in the presence of TPO for 9 days
were stimulated with 10 nM convulxin or 100 mg/ml collagen for 6 min
at 37° with agitation. Proteins from nonstimulated (lane 1) or convulxin
(lane 2)- or collagen-stimulated (lane 3) megakaryocytes were separated
using 8.5% acrylamide gels, transferred on PVDF membranes, and
probed by immunoblotting with the anti-phosphotyrosine antibody
PY20. Detection was performed using a peroxidase-coupled anti-mouse
IgG antibody and chemiluminescence. In lanes 4 and 5, proteins from
nonstimulated or convulxin-stimulated platelets were analyzed using
the same method. In B, changes in convulxin- or collagen-induced
phosphorylation were studied according to megakaryocyte maturation.
CD341-derived cells were cultured in the presence of TPO (5 3 105
cells/sample) for 6 (lanes 1, 2, and 3), 9 (lanes 4, 5, and 6), or 14 days
(lanes 7, 8, and 9) and were not stimulated (lanes 1, 4, and 7) or
stimulated with 10 nM convulxin (lanes 2, 5, and 8) or 100 mg/ml
collagen (lanes 3, 6, and 9). Samples were prepared and analyzed as
described in A.
FIG. 10. Convulxin-induced PLCg2,
Syk, and FcR g chain phosphoryla-
tion in human megakaryocytes. Pro-
teins from megakaryocytes (lanes A) or
platelets (lanes B), nonstimulated or
stimulated by collagen or convulxin, were
immunoprecipitated using anti-PLCg2 or
anti-Syk antibodies. After SDS-polyacryl-
amide gel electrophoresis, proteins were
transferred to PVDF membranes. Mem-
branes were probed with the anti-
phosphotyrosine 4G10 antibody, stripped,
and reprobed with the anti-PLCg2 ant-
ibody or the anti-Syk antibody, respect-
ively. Detection was performed using sec-
ondary peroxidase-coupled antibodies
and chemiluminescence.
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of molecular regulation (37–39). The main platelet-restricted
genes such those of the GPIb complex, GPIIb and PF4, contain
binding sites in their promoters for GATA and Ets transcrip-
tion factors. Expression of megakaryocyte-specific genes is
down-regulated in GATA-12/2 mice (40). A second set of genes,
which includes thromboxane synthase and b1 tubulin, is reg-
ulated by p45NF-E2 (41–43). Expression of these genes is totally
inhibited in the p45NF-E22/2 megakaryocytes leading to the
absence of proplatelet formation (38, 42, 43). It has been sug-
gested that this set of genes is involved in platelet functions
and is expressed at late stages of differentiation. Recently, we
investigated the expression of thomboxane synthase during
human megakaryocyte differentiation and also found that its
expression started early during differentiation in contrast to b1
tubulin (44). The pattern of thromboxane synthase, GPVI, and
CD49b expression in megakaryocyte differentiation has many
similarities because the level of these proteins markedly in-
creased in the more mature megakaryocytes. It has been shown
that megakaryocyte-specific enhancer of the a2 integrin gene
contains two tandem AP1 binding sites that are consensus sites
for p45NF-E2 (45, 46). However, presently there is no evidence
that p45NF-E2 regulates transcription of the a2 integrin gene.
The promoter of the human GPVI gene is still unknown, and
the identity of the regulatory factors remains to be determined.
Polymorphisms in the a2 gene have been identified and
shown to result in a variability of a2b1 integrin density at the
platelet surface (26, 47). Polymorphisms are obvious even in
megakaryocytes, as indicated by the heterogeneous expression
of CD49b by megakaryocytes from the different donors that we
have analyzed.
Platelet membrane GPVI migrates with an apparent molec-
ular mass of 58 kDa under nonreducing conditions. The human
protein contains one N-glycosylation site and several presump-
tive sites for O-glycosylation on its extracellular domain (5, 7),
and the predicted molecular mass of the core protein is ;40
kDa. GPVI detected in megakaryocyte lysates by immunoblot-
ting or ligand blotting migrated with an apparent molecular
mass of 55–56 kDa, which is slightly lower than the mass of
platelet GPVI but slightly higher than the mass of N-deglyco-
sylated GPVI (54 kDa) when runned in parallel (data not
shown); this suggests that GPVI undergoes a final processing
step at the end of megakaryocyte maturation.
Despite the fact that the GPVI molecular mass is slightly
different in megakaryocytes than in platelets, it associates with
the FcR g chain and is functional in megakaryocytes. Expres-
sion of GPVI allows megakaryocytes to bind to convulxin in
solution and to adhere to immobilized convulxin and immobi-
lized collagen in a Mg21-independent manner. Furthermore,
collagen and convulxin trigger GPVI-coupled signals in
megakaryocytes. This finding is in agreement with the results
of Melford et al. (34) and Mountford et al. (36) showing that
collagen-related peptides induces a rise in intracellular [Ca21]
in mature murine megakaryocytes and protein tyrosine phos-
phorylation in human megakaryocytes. At the earlier stages of
maturation (day 5–6), the amount of GPVI expressed on
megakaryocyte surface is probably too low for stable adhesion
to immobilized convulxin or collagen. However, it signifies that
several proteins are tyrosine-phosphorylated upon incubation
with convulxin in solution, indicating that GPVI dimerization
occurs in these conditions. Thus, our results indicate that, as
soon as it is expressed, GPVI has the potential to bind to the
ubiquitously expressed FcR g chain and to trigger signaling.
Later in differentiation (day 9), an increase in GPVI expression
allows megakaryocyte adhesion to immobilized convulxin. At
the end of maturation, the decreased level of GPVI-coupled
protein tyrosine phosphorylation suggests that GPVI might be
uncoupled from its signaling pathway by a mechanism that
remains to be determined. At the same moment, the role of
a2b1 integrin appears to become predominant in cellular inter-
action with collagen. These results are in agreement with the
respective role of a2b1 integrin and GPVI in platelets. It has
been already shown that a2b1 integrin plays a major role in
mature megakaryocyte (48) and megakaryocytic cell line adhe-
sion (46). In mature mouse megakaryocytes, the cross-linking
of a2b1 integrin has been reported to increase intracellular
[Ca21] via calcium influx and independently of Src and Syk
activation (35). From these results, it was suggested that col-
lagen triggers [Ca21]i increase in mature megakaryocytes via
multiple receptors including GPVI, causing calcium mobiliza-
tion and a2b1 integrin, which stimulates an influx of extracel-
lular calcium (35). Our observations that a2b1 integrin involve-
ment in collagen-mediated megakaryocytes adhesion increases
with maturation and that simultaneously GPVI-triggered sig-
nals decrease at the latest stages of maturation provide further
evidence that a2b1 integrin may be more important than GPVI
for mature megakaryocyte adhesion. Collagen interaction with
megakaryocytes and platelets may have different physiological
consequences. Although collagen interaction with platelets is
associated with activation, leading them to an irreversible
process, collagen interactions with megakaryocytes may have a
different role depending on the stage of maturation. One can
hypothesize that collagen contributes to localizing the imma-
ture progenitors in bone marrow at sites where conditions for
proliferation and maturation are optimal. Alternatively, at the
end of maturation, collagen could contribute to cell migration of
mature megakaryocytes and to their subsequent exit into cir-
culation. Whatever its role, when platelets are released they
must be fully functional, which means that no activation pro-
cesses between GPVI and collagen should happen during their
formation. How this occurs remains to be understood. Some
types of collagen do not activate platelets, and they may trigger
adhesion without activation in the sites of platelet release.
Alternatively, the signaling pathway of the GPVIzFcRg com-
plex may be inefficient or inhibited in megakaryocytes and
young platelets.
In conclusion, our results indicate that collagen receptors
like GPVI and CD49b are expressed by megakaryocytes at an
early stage of maturation and that they are fully functional
later in differentiation. The characterization of their role in
megakaryocyte interactions with collagen should allow a better
comprehension of diseases such as platelet production defects.
REFERENCES
1. Barnes, M. J., Knight, C. G., and Farndale, R. W. (1998) Curr. Opin. Hematol.
5, 314–320
2. Monnet, E., and Fauvel-Lafeve, F. (2000) J. Biol. Chem. 275, 10912–10917
3. Asselin, J., Gibbins, J. M., Achison, M., Lee, Y. H., Morton, L. F., Farndale,
R. W., Barnes, M. J., and Watson, S. P. (1997) Blood 89, 1235–1242
4. Jandrot-Perrus, M., Lagrue, A. H., Okuma, M., and Bon, C. (1997) J. Biol.
Chem 272, 27035–27041
5. Clemetson, J. M., Polgar, J., Magnenat, E., Wells, T. N., and Clemetson, K. J.
(1999) J. Biol. Chem. 274, 29019–29024
6. Miura, Y., Okuma, M., Jung, S. M., and Moroi, M. (2000) Thromb. Res. 98,
301–309
7. Jandrot-Perrus, M., Busfield, S., Lagrue, A.-H., Xiong, X., Debili, N.,
Chickering, T., Le Couedic, J.-P., Goodearl, A., Dussault, B., Fraser, C.,
Vainchenker, W., and Villeval, J. L. (2000) Blood 96, 1798–1807
8. Gibbins, J. M., Okuma, M., Farndale, R., Barnes, M., and Watson, S. P. (1997)
FEBS Lett. 413, 255–259
9. Tsuji, M., Ezumi, Y., Arai, M., and Takayama, H. (1997) J. Biol. Chem. 272,
23528–23531
10. Ezumi, Y., Shindoh, K., Tsuji, M., and Takayama, H. (1998) J. Exp. Med. 188,
267–276
11. Poole, A., Gibbins, J. M., Turner, M., van Vugt, M. J., van de Winkel, J. G.,
Saito, T., Tybulewicz, V. L., and Watson, S. P. (1997) EMBO J. 16,
2333–2341
12. Watson, S. P., and Gibbins, J. (1998) Immunol. Today 19, 260–265
13. Rabellino, E. M., Nachman, R. L., Williams, N., Winchester, R., and Ross, G. D.
(1979) J. Exp. Med. 149, 1273–1287
14. Vinci, G., Tabilio, A., Deschamps, J.-F., Van Haeke, D., Henri, A., Guichard, J.,
Expression and Function of Collagen Receptor GPVI15324
Tetteroo, P., Lansdorp, P. M., Hercend, T., Vainchenker, W., and
Breton-Gorius, J. (1984) Br. J. Haematol. 56, 589–605
15. Murray, L. J., Mandich, D., Bruno, E., DiGiusto, R. K., Fu, W. C., Sutherland,
D. R., Hoffman, R., and Tsukamoto, A. (1996) Exp. Hematol. 24, 236–245
16. Tronik-LeRoux, D., Roullot, V., Schweitzer, A., Berthier, R., and Marguerie, G.
(1995) J. Exp. Med. 181, 2141–2151
17. Debili, N., Issaad, C., Masse, J. M., Guichard, J., Katz, A., Breton-Gorius, J.,
and Vainchenker, W. (1992) Blood 80, 3022–3035
18. Lepage, A., Uzan, G., Touche, N., Morales, M., Cazenave, J. P., Lanza, F., and
de la Salle, C. (1999) Blood 94, 3366–3380
19. Francischetti, I. M., Saliou, B., Leduc, M., Carlini, C. R., Hatmi, M., Randon,
J., Faili, A., and Bon, C. (1997) Toxicon 35, 1217–1228
20. Kilpatrick, K. E., Cutler, T., Whitehorn, E., Drape, R. J., Macklin, M. D.,
Witherspoon, S. M., Singer, S., and Hutchins, J. T. (1998) Hybridoma 17,
569–576
21. Sugiyama, T., Okuma, M., Ushikubi, F., Sensaki, S., Kanaji, K., and Uchino,
H. (1987) Blood 69, 1712–1720
22. Coller, B., Beer, J., Scudder, L., and Steinberg, M. (1989) Blood 74, 182–192
23. Debili, N., Wendling, F., Katz, A., Guichard, J., Breton-Gorius, J., Hunt, P.,
and Vainchenker, W. (1995) Blood 86, 2516–2525
24. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156–159
25. Lagrue, A. H., Francischetti, I. M., Guimaraes, J. A., and Jandrot-Perrus, M.
(1999) FEBS Lett. 448, 95–100
26. Kunicki, T. J., Orchekowski, R., Annis, D., and Honda, Y. (1993) Blood 82,
2693–2703
27. Nakamura, T., Jamieson, G. A., Okuma, M., Kambayashi, J., and Tandon,
N. N. (1998) J. Biol. Chem. 273, 4338–4344
28. Nakamura, T., Kambayashi, J., Okuma, M., and Tandon, N. N. (1999) J. Biol.
Chem. 274, 11897–11903
29. Santoro, S. A. (1986) Cell 46, 913–920
30. Polgar, J., Clemetson, J. M., Kehrel, B. E., Wiedemann, M., Magnenat, E. M.,
Wells, T. N., and Clemetson, K. J. (1997) J. Biol. Chem. 272, 13576–13583
31. Watson, S. P. (1999) Thromb. Haemost. 82, 365–376
32. Faili, A., Randon, J., Francischetti, I. M. B., Vargaftig, B. B., and Hatmi, M.
(1994) Biochem. J. 298, 87–92
33. Tavassoli, M., and Aoki, M. (1981) Br. J. Haematol. 48, 25–29
34. Melford, S. K., Turner, M., Briddon, S. J., Tybulewicz, V. L., and Watson, S. P.
(1997) J. Biol. Chem. 272, 27539–27542
35. Briddon, S. K., Turner, M., Tybulewicz, V., and Watson, S. P. (1999) Blood 93,
3847–3855
36. Mountford, J. C., Melford, S. K., Bunce, C. M., Gibbins, J., and Watson, S. P.
(1999) Thromb. Haemost. 82, 1153–1159
37. Lemarchandel, V., Ghysdael, J., Mignotte, V., Rahuel, C., and Rome´o, P. H.
(1993) Mol. Cell. Biol. 13, 668–676
38. Shivdasani, R. A., Rosenblatt, M. F., Zucker-Franklin, D., Jackson, C. W.,
Hunt, P., Saris, C. J. M., and Orkin, S. H. (1995) Cell 81, 695–704
39. Shivdasani, R. A., Fujiwara, Y., McDevitt, M. A., and Orkin, S. H. (1997)
EMBO J. 16, 3965–3973
40. Vyas, P., Ault, K., Jackson, C. W., Orkin, S. H., and Shivdasani, R. A. (1999)
Blood 93, 2867–2875
41. Deveaux, S., Cohen-Kaminsky, S., Shivdasani, R. A., Andrews, N. C., Filipe,
A., Kuzniak, I., Orkin, S. H., Rome´o, P. H., and Mignotte, V. (1997) EMBO
J. 16, 5654–5661
42. Lecine, P., Villeval, J. L., Vyas, P., Swencki, B., Xu, Y., and Shivdasani, R. A.
(1998) Blood 92, 1608–1616
43. Lecine, P., Italiano, J. E., Kim, S. W., Villeval, J. L., and Shivdasani, R. A.
(2000) Blood 96, 1366–1373
44. Vitrat, N. Letestu, R., Masse´, A., Lazar, V., Vainchenker, W., and Debili, N.
(2000) Thromb. Haemost. 83, 759–768
45. Zutter, M. M., Painter, A. D., and Yang, X. (1999) Blood 93, 1600–1611
46. Zutter, M. M., Painter, A. A., Staatz, W. D., and Tsung, Y. L. (1995) Blood 86,
3006–3014
47. Kunicki, T. J., Kritzik, M., Annis, D. S., and Nugent, D. J. (1997) Blood 89,
1939–1943
48. Mossuz, P., Schweitzer, A., Molla, A., and Berthier, R. (1997) Br. J. Haematol.
98, 819–827
Expression and Function of Collagen Receptor GPVI 15325
